Table 2.
Diversity in treatment options and chemotherapy response for acute or lymphoma type of adult T‐cell leukemia/lymphoma (ATL)
| Subtype and condition | Systematic chemotherapy received, n | First systematic chemotherapy regimens n (% of row) | P | Chemotherapy responses n (% of row) | P | Allo‐HSCT received n (% of row) | P | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VCAP‐AMP‐VECP regimen or the like | CHOP regimen or the like | Others a | CR | PR | SD (NC) | PD | Unkown | ||||||
| Acute type | |||||||||||||
| Chemotherapy received, all | 343 | 161 (46.9) | 132 (38.5) | 50 (14.6) | 49 (14.3) | 169 (49.3) | 39 (11.4) | 67 (19.5) | 19 (5.5) | 62 | |||
| Age at diagnosis | |||||||||||||
| <70 y | 198 | 122 (61.6) | 60 (30.3) | 16 (8.1) | <.0001 | 40 (20.5) | 90 (46.2) | 24 (12.3) | 32 (16.4) | 9 (4.6) | .0024 | 61 (30.8) | <.0001 |
| ≥70 y | 145 | 39 (26.9) | 72 (49.7) | 34 (23.4) | 9 (6.3) | 79 (55.6) | 15 (10.6) | 35 (24.7) | 4 (2.8) | 1 (0.7) | |||
| ECOG PS | |||||||||||||
| PS 0,1 | 188 | 96 (51.0) | 67 (35.6) | 25 (13.3) | .27 | 36 (19.4) | 90 (48.4) | 17 (9.1) | 39 (20.4) | 5 (2.7) | .05 | 50 (26.6) | <.0001 |
| PS 2‐4 | 149 | 63 (42.3) | 61 (40.9) | 25 (16.8) | 13 (9.0) | 75 (51.7) | 22 (15.2) | 28 (19.3) | 7 (4.8) | 12 (8.1) | |||
| Unknown | 6 | ||||||||||||
| Hypercalcemia | |||||||||||||
| Absent | 234 | 116 (49.6) | 89 (38.0) | 29 (12.4) | .19 | 38 (16.5) | 109 (47.4) | 29 (12.6) | 45 (19.6) | 9 (3.9) | .49 | 49 (20.9) | .14 |
| Present | 100 | 41 (41.0) | 40 (40.0) | 19 (19.0) | 10 (10.2) | 55 (56.1) | 10 (10.2) | 20 (20.4) | 3 (3.1) | 12 (10.4) | |||
| Unknown | 9 | ||||||||||||
| B symptoms | |||||||||||||
| Absent | 225 | 113 (50.2) | 74 (32.9) | 38 (16.9) | .009 | 32 (14.2) | 113 (50.2) | 26 (11.6) | 40 (17.8) | 14 (6.2) | .4 | 43 (19.4) | .65 |
| Present | 103 | 40 (38.8) | 52 (50.5) | 11 (10.7) | 14 (13.6) | 50 (48.5) | 13 (12.6) | 23 (22.3) | 3 (2.9) | 17 (16.7) | |||
| Unknown | 15 | ||||||||||||
| Lymphoma type | |||||||||||||
| Chemotherapy received, all | 175 | 78 (44.6) | 73 (41.7) | 24 (13.7) | 39 (22.3) | 79 (45.1) | 26 (14.9) | 26 (14.9) | 5 (2.8) | 20 | |||
| Age at diagnosis | |||||||||||||
| <70 y | 85 | 49 (57.6) | 32 (37.7) | 4 (4.7) | .0002 | 27 (31.7) | 35 (41.2) | 5 (5.9) | 15 (17.7) | 3 (33.5) | .001 | 20 (23.5) | <.0001 |
| ≥70 y | 90 | 29 (32.2) | 41 (45.6) | 20 (22.2) | 12 (13.5) | 44 (49.4) | 21 (23.6) | 11 (12.4) | 1 (1.1) | 0 | |||
| ECOG PS | |||||||||||||
| PS 0,1 | 112 | 51 (45.5) | 47 (42.0) | 14 (12.5) | 31 (27.7) | 50 (44.6) | 15 (13.4) | 13 (11.6) | 3 (2.7) | .12 | 17 (15.2) | .12 | |
| PS 2‐4 | 57 | 23 (40.4) | 24 (42.1) | 10 (17.5) | .63 | 7 (12.5) | 26 (46.4) | 9 (16.1) | 13 (23.1) | 1 (1.8) | 3 (5.3) | ||
| Unknown | 6 | ||||||||||||
| Hypercalcemia | |||||||||||||
| Absent | 146 | 68 (46.6) | 57 (39.0) | 21 (14.4) | .47 | 32 (22.1) | 67 (46.2) | 21 (14.5) | 23 (15.9) | 2 (1.4) | .27 | 15 (10.3) | .65 |
| Present | 25 | 9 (36.0) | 13 (52.0) | 3 (12.0) | 6 (24.0) | 29 (36.0) | 5 (20.0) | 3 (12.0) | 2 (8.0) | 4 (16.0) | |||
| Unknown | 4 | ||||||||||||
| B symptoms | |||||||||||||
| Absent | 127 | 59 (46.4) | 50 (39.4) | 18 (14.2) | .27 | 27(21.3) | 62 (48.8) | 21 (16.5) | 13 (10.2) | 4 (3.1) | .04 | 15 (10.3) | .2 |
| Present | 41 | 14 (34.1) | 22 (53.7) | 5 (12.2) | 9 (22.0) | 16 (39.0) | 3 (7.3) | 12 (29.3) | 1 (2.4) | 4 (9.8) | |||
| Unknown | 7 | ||||||||||||
Abbreviations: allo‐HSCT, allogeneic hematopoietic stem cell transplantation; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CR, complete response; ECOG, Eastern Cooperative Oncology Group; NC, no change; PD, progressive disease; PR, partial response; PS, performance status; SD, stable disease, VCAP‐AMP‐VECP, vincristine, cyclophosphamide, doxorubicin and prednisone, followed by doxorubicin, ranimustine, and prednisoneand then by vindesine, etoposide, carboplatin, and prednisone.
a
Other miscellaneous regimens are summarized in Table S1.